Citius Pharmaceuticals reports fiscal Q3 2026 results as LYMPHIR launch continuesAug 14Quarterly updateCitius Pharmaceuticals, Inc.denileukin diftitox-cxdl
Citius Oncology reports LYMPHIR order growth in fiscal Q3 2026, expands sales forceAug 14Quarterly updateCitius Oncology, Inc.Citius Pharmaceuticals, Inc.
Citius Oncology adds Jonathan Peri to board, expanding to nine membersAug 12PeopleCitius Oncology, Inc.
Sign inSign in